Injection

Prevention of Hepatitis A Virus Infection in the US: Recommendations of the ACIP

Jul 02, 2020 | Kimberly Sharpe-Scott

The CDC, in collaboration with the Advisory Committee on Immunization Practices (ACIP), published new recommendations for hepatitis A vaccination. The recently released MMWR, Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020, highlights the following key messages:

  • Hepatitis A vaccines were first recommended by ACIP in 1996 and the last full recommendations and report was published 14 years ago in 2006, when ACIP recommended routine hepatitis A vaccination of all children aged 12–23 months.
  • The hepatitis A virus (HAV) is transmitted via the fecal-oral route, usually through direct person-to-person contact or consumption of contaminated food or water.
  • Illness is usually mild and self-limited when healthy persons are infected, however disease severity increases in persons who are older or immunocompromised, have chronic liver disease, or have other underlying health conditions.
  • After the introduction of hepatitis A vaccination in 1996, reported hepatitis A cases fell over 95% between 1996 and 2011.
  • Since then small increases in cases occurred in 2013 and 2016 attributed to foodborne outbreaks associated with contaminated food; then, beginning in 2016, greater increases in the number of reported cases occurred across the United States, primarily from widespread outbreaks of hepatitis A from person-to-person transmission resulting in a sharp increase in cases from 2,007 in 2016 to 12,474 in 2018.
  • Low adult HepA vaccination coverage and high population susceptibility to HAV infection allow outbreaks to continue to occur.
  • These outbreaks have led the Advisory Committee on Immunization Practices to review the data on vaccination and prepare new hepatitis A recommendations to decrease HAV incidence and prevent future outbreaks.

The new and updated ACIP recommendations include, but are not limited to:

  • Vaccination of all children and adolescents aged 2–18 years who have not previously received HepA vaccine (catch-up vaccination)
  • Vaccination of all persons aged ≥1 year infected with human immunodeficiency virus (HIV)
  • Vaccination of pregnant women who are identified to be at risk for HAV infection during pregnancy or for having a severe outcome from HAV infection
  • Vaccination during hepatitis A outbreaks of persons aged ≥1 year who are at risk for HAV infection or who are at risk for severe disease from HAV
  • Vaccination in settings providing services to adults in which a high proportion of persons have risk factors for HAV infection (e.g., health care settings with a focus on those who use injection or non-injection drugs, group homes, and nonresidential day care facilities for developmentally disabled persons)

Access the recently released MMWR detailing updated hepatitis A vaccination recommendations here.


About Kimberly Sharpe-Scott

More posts by Kimberly Sharpe-Scott

Related Posts

NACCHO Cognitive Health Guide FINAL 1
  • Tools & Resources
  • Healthy Aging
  • Healthy Living & Prevention
  • Mobilizing for Action through Planning and Partnerships (MAPP)

New NACCHO Resource: Integrating Brain Health into...

NACCHO, in partnership with the Alzheimer’s Association, is thrilled to launch...

Mar 01, 2024 | Andrea Grenadier

New NACCHO Resource: Integrating Brain Health into...

  • HIV, STI, & Viral Hepatitis
  • HIV, STI, Viral Hepatitis, and Harm Reduction Digest

Digest (February 28, 2024)

HIV, STI, Viral Hepatitis, and Harm Reduction Digest: February 28, 2024

Mar 01, 2024

Digest (February 28, 2024)

EHE Superstars Investing in Community Voices in LA County
  • HIV, STI, & Viral Hepatitis

EHE Superstars: Investing in Community Voices in LA...

This blog continues our new series highlighting collaborative projects between...

Feb 28, 2024 | Anthony Green

EHE Superstars: Investing in Community Voices in LA...

I Stock 1490413668
  • Emergency Response
  • Maternal, Child, & Adolescent Health

Announcing NACCHO’s 2023-2024 Virtual Learning...

NACCHO, with support from the Centers for Disease Control and Prevention’s...

Feb 16, 2024 | Harpur Schwartz, Elana Filipos

Announcing NACCHO’s 2023-2024 Virtual Learning...

Untitled
  • Antibiotic Resistance
  • Community Health
  • Healthcare-Associated Infections
  • ID Featured

NACCHO’s Healthcare Infection Prevention and Control...

The NACCHO Healthcare IPC Summit, supported by CDC Project Firstline, aims to...

Feb 14, 2024 | Jaclyn Abramson

NACCHO’s Healthcare Infection Prevention and Control...

  • HIV, STI, & Viral Hepatitis
  • HIV, STI, Viral Hepatitis, and Harm Reduction Digest

Valentine’s Day Digest (February 14, 2024)

HIV, STI, Viral Hepatitis, and Harm Reduction Digest: February 14, 2024

Feb 14, 2024

Valentine’s Day Digest (February 14, 2024)

I Stock 1131109283
  • Funding Opportunity
  • COVID-19
  • Immunization
  • Partnerships

Request for Proposals: Technical Assistance to Improve...

NACCHO, with support from the Centers for Disease Control and Prevention (CDC),...

Feb 12, 2024 | Tori Decea

Request for Proposals: Technical Assistance to Improve...

I Stock 1791470316
  • Funding Opportunity
  • AmeriCorps
  • Communications & Public Relations
  • Opportunity

Request for Proposals: Communications Consultant for...

NACCHO, in partnership with CDC, is seeking a consultant to create a series of...

Feb 12, 2024 | Andrea Grenadier

Request for Proposals: Communications Consultant for...

  • HIV, STI, & Viral Hepatitis

Balanced Imperfection Harm Reduction Services Survey is...

Balanced Imperfection, with funding from NACCHO, is honored to be able to...

Feb 12, 2024

Balanced Imperfection Harm Reduction Services Survey is...

Back to Top